ARDS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARDS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Aridis Pharmaceuticals's Operating Income for the three months ended in Sep. 2023 was $-0.87 Mil. Aridis Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Aridis Pharmaceuticals's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Aridis Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Aridis Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Interest Coverage | Get a 7-Day Free Trial | No Debt | No Debt | N/A | - | - |
Aridis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Interest Coverage | Get a 7-Day Free Trial | - | N/A | N/A | N/A | N/A |
For the Biotechnology subindustry, Aridis Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Aridis Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Aridis Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as
Here, for the fiscal year that ended in Dec. 2022, Aridis Pharmaceuticals's Interest Expense was $-0.12 Mil. Its Operating Income was $-29.99 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.29 Mil.
Aridis Pharmaceuticals did not have earnings to cover the interest expense. |
Aridis Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as
Here, for the three months ended in Sep. 2023, Aridis Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-0.87 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.85 Mil.
GuruFocus does not calculate Aridis Pharmaceuticals's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
Aridis Pharmaceuticals (OTCPK:ARDS) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Fibrosis Foundation Cystic | 10 percent owner | 4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814 |
Hasan Jafri | officer: Chief Medical Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
Vu Truong | director, 10 percent owner, officer: CEO, CSO, Director | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Eric Patzer | director, 10 percent owner | 5941 OPTICAL CT., SAN JOSE CA 95138 |
John F Hamilton | director | 1360 O'BRIEN DR, MENLO PARK CA 94025 |
Michael Adrian Nazak | officer: Chief Financial Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
Susan Richards Windham-bannister | director | 78 BLANCHARD ROAD, BURLINGTON MA 01803 |
Isaac Blech | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Fred Kurland | officer: Chief Financial Officer | C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Wolfgang Dummer | officer: Chief Medical Officer | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Robert R Ruffolo | director | |
Shawn Lu | director | C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326 |
Robert K. Coughlin | director | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Craig S Gibbs | director | C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
From GuruFocus
By sperokesalga sperokesalga • 06-08-2023
By PRNewswire PRNewswire • 06-23-2022
By ACCESSWIRE • 06-30-2023
By Value_Insider Value_Insider • 12-12-2022
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 05-25-2023
By ACCESSWIRE • 09-15-2023
By Marketwired • 08-02-2023
By ACCESSWIRE ACCESSWIRE • 06-30-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.